Clinical trials: Critical Bone Defects
Tibial Fractures
rhBMP-2 Versus Autograft in Critical Size Tibial Defects
The purpose of our study is to evaluate the use of recombinant human bone morphogenetic protein 2 (RhBMP-2) as compared to standard ICBG in the treatment of severe open tibia fractures with a critical size bone defect (at least…
- Trial name
- NCT00853489
- Testing
- recombinant bone morphogenetic protein 2, Autogenous iliac crest bone graft
- Where
- 13 sites in United States
- Volunteers
- 33 people
- Sponsor
- St. Louis University